Resources

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

Lewis Miles discusses changes to EMIs, EISs and VCTs coming into force.

Fermtech has raised £2.5m to scale Koji Cocoa™, a fermentation-based cocoa ingredient made from cocoa shells that delivers 25–33% cost savings and up to 98% lower carbon emissions.

British Growth Partnership Fund I achieves a first close of £200 million, with commitments from Aegon UK, Cushon Master Trust, M&G, and the British Business Bank.

Semarion has raised $3.8 million USD (£2.9 million GBP)

I’m pleased to share that we are part of a new Government and industry joint taskforce to drive innovation in the UK’s commercial environment for medicines, announced last week as part of government ambitions for the Life Sciences Strategy.

Mestag Therapeutics announced the closing of a $40 million financing

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

There are a number of significant moving pieces right now in the sector, including the major strategic shift at UKRI and Innovate launched last Thursday.

New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.

Sonjoy Brahma, tranScrip’s VP of Clinical Operations, joins Joab Williamson of Faron Pharmaceuticals to unpack the operational realities of life in a small emerging biotech. They’ll explore the pressures of rare oncology development, how cash runway and clinical milestones shape decision-making and why flexibility, external expertise and careful planning are essential to moving programmes forward with confidence.

The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.

In this guest blog, Valerie Pinkerton, UK TNFD & Transition Plans Lead at the Green Finance Institute, explores why nature-related risks are becoming increasingly important for the pharmaceutical and biotechnology sector.

BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline.

C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics.

Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.

Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.

Rare Disease Day on Saturday was a moment to reflect on the momentum building, and to check in on the progress of the UK Rare Disease Framework.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced a £4.8 million (c. $6.5 million) extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to £18.8 million (c. $25.4 million).

With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.